Infliximab (inflix) for Crohn’s disease (CD)*
| Patient group | Outcomes | Number of patients | Dose | Inflix | Placebo | RBI (95% CI) | NNT (CI) |
|---|---|---|---|---|---|---|---|
| Fistulising CD | ≥ 50% closure at 18 weeks | 94 | 5 mg, 10 mg | 62% | 26% | 140% (37 to 363) | 3 (2 to 7) |
| Treatment- | Response at 4 weeks | 108 | 5 mg, 10 mg, 20 mg | 65% | 16% | 307% (84 to 928) | 3 (2 to 4) |
| resistant CD | Response at 12 weeks | 108 | 5 mg, 10 mg, 20 mg | 41% | 12% | 241% (31 to 908) | 3 (2 to 12) |
| Response at 12 weeks | 108 | 5 mg, 10 mg, 20 mg | 24% | 8.0% | 201% (–10 to 10) | Not significant |
| Repeat doses | Single dose | ||||||
|---|---|---|---|---|---|---|---|
| *Abbreviations defined in glossary; RBI, NNT, and CI calculated from data in article. †Interim data reported from a 102-week ongoing trial of maintenance infliximab. | |||||||
| Response at 30 weeks† | 335 | 5 mg, 10 mg v 5 mg | 55% | 27% | 102% (48 to 183) | 4 (3 to 6) | |
| Response at 30 weeks† | 335 | 5 mg, 10 mg v 5 mg | 42% | 21% | 100% (37 to 199) | 5 (4 to 10) | |